- Home
- DCGO vs MXCT Comparison
DCGO vs MXCT Comparison
Compare DCGO & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- MXCT
- Stock Information
- Founded
- DCGO 2015
- MXCT 1999
- Country
- DCGO United States
- MXCT United States
- Employees
- DCGO N/A
- MXCT N/A
- Industry
- DCGO Managed Health Care
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DCGO Health Care
- MXCT Health Care
- Exchange
- DCGO Nasdaq
- MXCT Nasdaq
- Market Cap
- DCGO 417.4M
- MXCT 398.3M
- IPO Year
- DCGO N/A
- MXCT 2021
- Fundamental
- Price
- DCGO $4.12
- MXCT $3.45
- Analyst Decision
- DCGO Strong Buy
- MXCT Strong Buy
- Analyst Count
- DCGO 5
- MXCT 3
- Target Price
- DCGO $6.10
- MXCT $8.67
- AVG Volume (30 Days)
- DCGO 730.0K
- MXCT 599.5K
- Earning Date
- DCGO 11-07-2024
- MXCT 11-06-2024
- Dividend Yield
- DCGO N/A
- MXCT N/A
- EPS Growth
- DCGO 300.38
- MXCT N/A
- EPS
- DCGO 0.29
- MXCT N/A
- Revenue
- DCGO $694,968,328.00
- MXCT $45,599,000.00
- Revenue This Year
- DCGO $1.17
- MXCT N/A
- Revenue Next Year
- DCGO N/A
- MXCT $21.59
- P/E Ratio
- DCGO $14.44
- MXCT N/A
- Revenue Growth
- DCGO 30.19
- MXCT 19.85
- 52 Week Low
- DCGO $2.75
- MXCT $3.17
- 52 Week High
- DCGO $6.21
- MXCT $5.55
- Technical
- Relative Strength Index (RSI)
- DCGO 65.99
- MXCT 44.48
- Support Level
- DCGO $3.84
- MXCT $3.17
- Resistance Level
- DCGO $4.43
- MXCT $3.61
- Average True Range (ATR)
- DCGO 0.26
- MXCT 0.25
- MACD
- DCGO 0.02
- MXCT -0.01
- Stochastic Oscillator
- DCGO 71.63
- MXCT 28.93
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.